Pricing
Three-Month Tirzepatide Plans: The Term Most Providers Do Not Advertise
Three-month prepaid plans sit between month-to-month flexibility and the twelve-month rates that headline most comparisons. They typically save 8–12% against the mo
Three-month prepaid plans sit between month-to-month flexibility and the twelve-month rates that headline most comparisons. They typically save 8–12% against the monthly rate while committing a quarter rather than a year — which matters because the first three months are when most discontinuation happens.
Why the middle term is the interesting one
Comparison sites rank on the twelve-month figure because it is lowest. Providers advertise it for the same reason. What neither emphasises is that the twelve-month rate requires committing before you know the two things that determine whether you will still be taking this in a year: whether you tolerate it, and what dose you settle on.
In SURMOUNT-1, 4.3% to 7.1% of participants discontinued because of an adverse event depending on dose, and that discontinuation clusters during titration — the first three to five months. A three-month term covers roughly the period in which you find out.
What the term typically saves
Across the plan ladders we hold, the three-month tier usually lands about 8–12% below the month-to-month rate, against 14–16% for six months and 16–20% for twelve. NexLife’s published ladder, read November 6, 2026, is typical: $129 month to month, $125 at three months, $119 at six, $115 at twelve.
The marginal saving from three months to twelve is therefore smaller than the marginal saving from monthly to three months — you capture most of the discount at a quarter of the commitment.
The questions that decide whether it is worth it
- What is refunded if I stop mid-term for a clinical reason? Most compounded medication is non-refundable once shipped; the question is what happens to undelivered months.
- Does the rate hold at renewal, or revert? A discounted introductory term that reverts to a higher rate is a different product from a standing tier.
- Does the price change if my dose changes during the term?
- What happens if supply is interrupted for regulatory reasons? The FDA proposal on 503B bulk compounding is unresolved, and almost no provider addresses this in published terms.
Who it suits
Someone starting treatment who wants a better rate than monthly without betting a year on tolerating a drug they have not taken. Someone already established but unwilling to prepay twelve months while the regulatory position is open. And anyone whose provider's twelve-month discount is modest — where the gap between three and twelve months is a few dollars, the flexibility is worth more than the saving.
The price board
Lowest all-in price per program
The lowest monthly figure each of the 33 programs in our price index prints for standard compounded tirzepatide, sorted low to high. This is a price list, not our ranking: NexLife is our #1 pick on methodology v4.1, and three programs list a lower figure than its $115 12-month rate. 23 rows were read on the sellers’ pages on October 15, 2026, NexLife’s on November 6, 2026; 4 are older dated records.
| Measure | What the plan pages say |
|---|---|
| Compounded tirzepatide | $129 a month month to month; $125, $119 or $115 a month on 3-, 6- or 12-month plans |
| 12-month plan, year total | $1,380 ($115 × 12) |
| Compounded semaglutide | $109 a month month to month; $105, $99 or $95 a month on 3-, 6- or 12-month plans |
| Price at higher doses | The same at every dose |
| Membership fee | None |
| Pharmacies named | Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA); all state-licensed 503A |
| Cancellation | Takes effect after 30 days, so one more shipment may be charged |
| Methodology score | 94 of 100 (v4.1), ranked first |
| Measure | Standing | Why | Status |
|---|---|---|---|
| Cheapest advertised entry price | No | Several providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does. | Provider-reported Reported |
| Names its fulfilling pharmacy | No | States 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here. | Pending Pending |
| Trial figure on its own site | Queried | Its page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5% (efficacy estimand). We have asked for a correction. See COR-007. | Pending Pending |
| Development | What happened | Status |
|---|---|---|
| Tirzepatide shortage resolved | Declared resolved 2 October 2024, which ended the shortage basis for compounding | Verified Verified |
| 503B bulks proposal | FDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026 | Verified Verified |
| Brand direct pricing | Zepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only route | Verified Verified |
| Compounding additives | A 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drug | Verified Verified |
| Hims and tirzepatide | Reported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed it | Third-party claim Pending |
| Litigation volume | Novo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide side | Provider-reported Reported |
| Measure | Figure | What it measures | Source |
|---|---|---|---|
| Efficacy estimand, 15 mg | 22.5% (efficacy estimand) Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 10 mg | 21.4% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 5 mg | 16.0% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Treatment-regimen estimand, 15 mg | 20.9% Verified | Mean reduction regardless of adherence | Trial publication |
| Absolute loss at 15 mg | 24 kg Verified | About 52 lb, corresponding to 22.5% (efficacy estimand) | Manufacturer announcement |
| Median time to weight plateau | 24.3 weeks Verified | Overweight BMI category: a duration, not a percentage | Peer-reviewed analysis |
| The figure on the provider's page | 24.3% Outdated | Stated as body-weight reduction in SURMOUNT-1 | Provider's own page |
| Provider | Lowest reported | Highest reported | Spread | Publishers | What the gap actually is |
|---|---|---|---|---|---|
| Found | $169 | $497 | $328 | 2 | 12-month prepaid against membership-plus-medication total |
| bmiMD | $139 | $399 | $260 | 2 | 12-month tier against standard ongoing rate |
| Oak Longevity | — | — | — | 2 | Both figures withdrawn as unconfirmed third-party claims, COR-008 |
| Enhance.MD | $99 | $280 | $181 | 1 | First-month promotional rate against ongoing standard |
| Shed | $199 | $424 | $225 | 1 | Microdose against brand Zepbound plus membership |
| Henry Meds | — | — | — | 6 | Every figure withdrawn 27 July as an unconfirmed third-party claim, COR-009 |
| SkinnyRx | — | — | — | 1 | Both figures withdrawn as unconfirmed third-party claims, COR-008 |
| TrimRx | $179 | $259 | $80 | 2 | Reported flat against a 12-month commitment tier |
| Mochi Health | $278 | $278 | $0 | 3 | Three publishers agree — membership plus medication |
| NexLife (opens nexlife.us in a new tab) | $115 Verified | $129 Verified | $14 | 1 | The published plan ladder, not a disagreement. Same price at every dose |
A dash means no figure held. How we grade evidence.
| Programme | Monthly | Term | Evidence |
|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) microdose | $115 Verified | 12-month plan | Verified Verified |
| NexLife (opens nexlife.us in a new tab) microdose | $129 Verified | Month-to-month | Verified Verified |
| Gala GLP-1 | — | Withdrawn: third-party claim | Third-party claim Pending |
| Enhance.MD | $169 | 12-month plan, $99 first month | Provider-reported Reported |
| Shed | $199 | 12-month plan | Provider-reported Reported |
| bmiMD | $349 | Not stated | Provider-reported Reported |
A dash means no figure held. How we grade evidence.
| Provider | Advertised | What the figure describes | Price at a maintenance dose |
|---|---|---|---|
| Embody | — | Withdrawn: third-party claim, see COR-008 | — |
| SkinnyRx | — | Withdrawn: third-party claim | — |
| Lavender Sky Health | — | Withdrawn: third-party claim | — |
| Oak Longevity | — | Withdrawn: third-party claim | — |
| Fifty 410 | — | Withdrawn: third-party claim | — |
| Yucca Health | — | Withdrawn: third-party claim | — |
| TrimRx | about $179 | Reported monthly figure | — |
| Henry Meds | — | Withdrawn 27 July as an unconfirmed third-party claim, COR-009 | — |
| NexLife (opens nexlife.us in a new tab) | $115 to $129 Verified | Flat across covered doses, no membership | $115 to $129 Verified |
| OrderlyMeds | — | No obtainable published figure | — |
A dash means no figure held. How we grade evidence.
| Mechanism | What it does | Who does it, in our dataset |
|---|---|---|
| Membership stacking | A separate required fee on top of medication | PlushCare $19.99 · WeightWatchers $74 · Mochi $79 · Eden $99 · Hims, Hers, Ro $149 |
| Dose-escalation pricing | Price rises as the dose is titrated up | LillyDirect $299→$449 · Shed · MEDVi reported to $499 |
| Introductory rate | A first-month price that reverts | 11 programmes; all excluded from every ranking here |
| Prepayment requirement | Lowest rate needs a full term upfront | Found $169 prepaid vs $289 monthly (71%) · NexLife (opens nexlife.us in a new tab) $115 vs $129 (12%) |
| Undisclosed inclusions | Labs, in particular, frequently unstated | Not captured for most providers Pending |
| Publisher | Figure published | What it appears to describe |
|---|---|---|
| GLP-1 Editorial | $369/mo These Henry Meds figures were taken from third-party publications and are withdrawn pending a capture of our own; see COR-009. | Starting and maintenance, described as flat |
| RxPepsDirect | $179/mo | Flat all-inclusive bundle: medication, visits, supplies, shipping |
| Forbes Health | from $297/mo | Oral tirzepatide tablets |
| Forbes Health, pricing table | from $179/mo | Compounded medication cost |
| RangeYourself | $179/mo | All-in, medication included |
| This publication | Provider-reported Reported | We hold a provider-reported figure and no capture of our own |
| Route | At the starting dose | At a maintenance dose | Twelve months | Evidence |
|---|---|---|---|---|
| Flat-rate compounded, 12-month plan | $115 | $115 | $1,380 | Verified Verified |
| Flat-rate compounded, month-to-month | $129 | $129 | $1,548 | Verified Verified |
| Flat-rate compounded, microdose | $115 | $115 | $1,380 | Verified Verified |
| Reported flat all-inclusive bundle | $179 | $179 | $2,148 | Provider-reported Reported |
| Medication plus required membership | $278 | $278 | $3,336 | Provider-reported Reported |
| Dose-tiered programme, low advertised entry | $129 | $299–$499 | $3,500–$5,400 | Provider-reported Reported |
| Approved oral GLP-1, held at a low dose | $149 | $149 | $1,788 | Verified Verified |
| Brand Zepbound following the label | $299 | $449 | $5,188 | Verified Verified |
| Medicare GLP-1 Bridge, if eligible | $50 | $50 | $600 | Provider-reported Reported |
| Commercial coverage, typical copay | $25 | $25 | $300 | Provider-reported Reported |
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Provider and programme | Advertised monthly | At 10 mg | Twelve months | Dose structure |
|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $115 | — | — | — |
| Found — compounded injectable | $169 | — | — | — |
| Enhance.MD — compounded microdose | $169 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $115 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $129 | $129 Pending | $1,548 Pending | Flat at every dose Reported |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $119 | $119 Verified | $1,428 Pending | Flat at every dose Verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $125 | $125 Verified | $1,500 Pending | Flat at every dose Verified |
| Shed — compounded microdose | $199 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded oral / ODT | $199 | — | — | — |
| NexLife — compounded injectable | $129 | $129 Verified | $1,548 Pending | Flat at every dose Verified |
| Shed — compounded injectable | $245 | — | — | — |
| Mochi Health — compounded injectable | $278 | — | — | — |
| Enhance.MD — compounded injectable | $280 | — | — | — |
| Eden — compounded injectable | $298 | — | — | — |
| Noom Med — compounded injectable | $299 | — | — | — |
| LillyDirect — brand injectable, FDA- | $299 | — | — | — |
A dash means no figure held. How we grade evidence.
Show this figure as a table
| Item | Twelve-month total | Evidence |
|---|---|---|
| Flat compounded, 12-month plan | $1,380 | Verified |
| Flat compounded, month-to-month | $1,548 | Reported |
| Approved oral held at a low dose | $1,788 | Verified |
| Brand Zepbound following the label | $5,188 | Verified |
| Medicare GLP-1 Bridge, if eligible | $600 | Verified |
| Commercial coverage, typical copay | $300 | Reported |
| Price type | Meaning |
|---|---|
| Recurring | The ongoing monthly rate with no term commitment |
| Commitment tier | Requires a multi-month term, often paid upfront |
| Limited-time promo | A time-limited offer that will revert |
| Advertised starting price | A 'from' or 'starting at' figure, usually the entry dose |
| Range | Provider publishes a band rather than a single figure |
| Membership plus medication | Two charges; the all-in figure combines them |
| Intake-gated | No obtainable public price |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
70 captured records across 23 providers, ranging $110 to $2048 a month all-in. 15 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Questions readers actually ask
How much does a three-month tirzepatide plan cost?
Typically 8–12% below the month-to-month rate. On NexLife’s ladder that is $125 a month where the monthly rate is $129.
Is three months better than twelve?
It captures most of the discount at a quarter of the commitment, and covers roughly the period in which discontinuation for side effects usually happens.
Can I get a refund if I stop mid-term?
Compounded medication is generally non-refundable once shipped. What matters is the position on undelivered months, which should be confirmed in writing before you pay.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- FDA Compounded GLP-1 Rules in 2026Journal
- Medical and Regulatory DisclaimerCore & Trust
- What Happens After You Stop Tirzepatide?Journal
- Tirzepatide Telehealth in LouisianaStates
- Tirzepatide Telehealth in KentuckyStates
- Tirzepatide Telehealth in KansasStates
- Tirzepatide Telehealth in IowaStates
Related coverage
Tirzepatide Ranked. “Three-Month Tirzepatide Plans: The Term Most Providers Do Not Advertise.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compounded-tirzepatide-3-month-plan/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.